Leaving MSDLink.ie
You are about to exit this MSD Ireland website. MSD Ireland makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by MSD Ireland.
This site is intended for health care professionals of Ireland.
Copyright © 2009-2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
tcm:4475-69905-4 Fosavance /products/fosavance/ sameWindow Primary tcm:4475-496682-64 010_About Fosavance 5600 about.xhtml tcm:4475-496683-64 020_Fracture Risk fracture-risk.xhtml tcm:4475-496684-64 030_Prevalence prevalence.xhtml tcm:4475-496685-64 040_10 Year Anti-Fracture Efficacy ten-year-anti-fracture-efficacy.xhtml tcm:4475-496686-64 050_Fracture Intervention Trial (FIT) fracture-intervention-trial.xhtml tcm:4475-496687-64 060_Importance of Vitamin D importance-of-vitamin-d.xhtml tcm:4475-496688-64 070_FOCUS D: Vitamin D Levels focus-d-vitamin-d-levels.xhtml tcm:4475-496689-64 080_FOCUS D: BMD Changes focus-d-bmd-changes.xhtml tcm:4475-496756-64 090_Efficacy: Systematic Review efficacy-systematic-review.xhtml tcm:4475-535888-64 100_Patient Benefits patient-benefits.xhtml tcm:4475-496690-64 110_Summary summary.xhtml tcm:4475-496691-64 120_Professional Resources professional-resources.xhtml tcm:4475-496692-64 122_-Support Materials support-materials.xhtml tcm:4475-496693-64 124_-Visuals and Videos visuals-videos.xhtml tcm:4475-496694-64 126_-Slide Sets slide-sets.xhtml tcm:4475-496696-64 130_Patient Resources patient-resources.xhtml tcm:4475-496697-64 132_-Patient Information patient-information.xhtml tcm:4475-496698-64 134_-Support Materials Resources support-materials-resources.xhtml tcm:4475-515837-64 140_Abridged Prescribing Information abridged-prescribing.xhtml tcm:4475-496701-64 LeftNav_Fosavance leftnav.xml tcm:4475-497122-64 Study Designs study-design.xhtml False
tcm:4475-496682-64
tcm:4475-496682-64 010_About Fosavance 5600 about.xhtml
tcm:4475-496682-64 010_About Fosavance 5600 about.xhtml
FOSAVANCE 5600 (alendronate sodium, colecalciferol (vitamin D3))
FOSAVANCE is therapeutically indicated for the treatment of postmenopausal osteoporosis in women who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency. FOSAVANCE reduces the risk of vertebral and hip fractures.
Once weekly FOSAVANCE 5600 contains 70 mg of alendronate plus 5600 IU ofvitamin D3, equivalent to 800 IU per day.
Please consult medicines.ie for further information
SPC: Click here
PIL: Click here